Tadeusz Przewłocki

Jagiellonian University, Cracovia, Lesser Poland Voivodeship, Poland

Are you Tadeusz Przewłocki?

Claim your profile

Publications (84)77.05 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION The results of the ABSORB trial showed the efficacy and safety of bioresorbable vascular scaffolds (BVS) and their unique advantage, namely, the restoration of vasomotion after full biodegradation. OBJECTIVES The aim of the registry was to evaluate procedural issues, angiographic results, and clinical outcomes of patients with acute coronary syndrome (ACS) treated with BVS implantation. PATIENTS AND METHODS The study included 100 patients. Cohort 1 comprised 46 patients with unstable angina; cohort 2, 38 patients with non-ST-segment elevation myocardial infarction; and cohort 3, 16 patients with ST-segment elevation myocardial infarction. RESULTS Predilation was performed in 93% of the patients. The final Thrombolysis In Myocardial Infarction (TIMI) 3 flow was achieved in 99% of the patients. In all patients, BVS was successfully implanted. In 81% of the patients, postdilation was performed with a balloon catheter with the same diameter as BVS; in 11%, with a balloon catheter with a diameter of 0.25 mm larger than BVS; and in 7%, with a balloon catheter with a diameter of 0.5 mm larger than BVS. We observed no no-reflow phenomenon, 1 distal embolization, and 2 slow-flow phenomena. Two major adverse cardiac events were reported, namely, periprocedural myocardial infarction in 2 patients. During 1-year follow-up, we observed only 1 additional myocardial infarction caused by stent thrombosis as well as 1 target lesion revascularization. CONCLUSIONS In our study, BVS in patients with ACS showed to be a safe and effective procedure.
    Polskie archiwum medycyny wewnȩtrznej 12/2014; 124(12):669-77. · 2.05 Impact Factor
  • Source
    TCT 2014; 09/2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background:The aim of this study was to prospectively perform ambulatory 24-h ECG monitoring to assess the effects of transcatheter closure of atrial septal defect (ASD).Methods and Results:A total of 235 consecutive subjects (female, n=163; male, n=72; age, 44.6±14.4 years) were enrolled in the study, who were due undergo ASD closure. Holter monitoring was performed before procedure and at 1, 6 and 12 months of follow-up. During the procedure transient supraventricular arrhythmia occurred in 8 patients (3.4%), and bradycardia in 3 (1.3%). In 3 patients (1.3%) an episode of atrial fibrillation occurred in the first hour after the procedure. In 8 patients (3.4%) transient first-degree atrioventricular block was noted. A significant increase in number of supraventricular extrasystoles (SVES)/24 h was noted 1 month after the procedure (P<0.001). On multiple forward stepwise regression analysis, device size and fluoroscopy time had an influence on increase in number of SVES seen 1 month after the procedure (P<0.001).Conclusions:Transcatheter closure of ASD is associated with a transient increase in supraventricular premature beats and a small risk of conduction abnormalities and paroxysmal atrial fibrillation in early follow-up. Transcatheter closure of ASD does not reduce arrhythmia that appears prior to ASD closure. Larger device size and longer procedure time are associated with increased risk of supraventricular arrhythmia on early follow-up.
    Circulation Journal 08/2014; 78(10). DOI:10.1253/circj.CJ-14-0456 · 3.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: IntroductionClosure of the atrial septal defect in patients with insignificant shunt is controversial.AimTo evaluate the outcomes of transcatheter closure of atrial septal defect (ASD) in symptomatic patients with borderline shunt.Material and methodsOne hundred and sixty patients (120 female, 40 male) with a mean age of 30.1 ±16.2 (20–52) years with a small ASD who underwent transcatheter closure were analyzed. All patients had a small ASD with Qp: Qs ratio ≤ 1.5, mean 1.2 ±0.9 (1.1–1.5) in echo examination. Cardiopulmonary exercise tests, clinical study, transthoracic echocardiographic study as well as quality of life (QoL) (measured using the SF36 questionnaire (SF36q)) were repeated in all patients before and after the procedure.ResultsThe devices were successfully implanted in all patients. After 12 months of ASD closure, all the patients showed a significant improvement of exercise capacity (oxygen consumption – 21.9 ±3.1 vs. 30.4 ±7.7, p > 0.001). The QoL improved in 7 parameters at 12-month follow-up. The mean SF36q scale increased significantly in 141 (88.1%) patients of mean 43.2 ±20.1 (7–69). A significant decrease of the right ventricular area (20.3 ±1.3 cm2 vs. 18.3 ±1.2 cm2, p < 0.001) and the right atrial area (15.2 ±1.9 cm2 vs. 12.0 ±1.6 cm2, p < 0.001) was observed at 12-month follow-up.ConclusionsClosure of ASD in the patients with insignificant shunt resulted in significant durable clinical and hemodynamic improvement after percutaneous treatment.
    Postepy w Kardiologii Interwencyjnej / Advances in Interventional Cardiology 06/2014; 10(2):78-83. DOI:10.5114/pwki.2014.43510 · 0.07 Impact Factor
    This article is viewable in ResearchGate's enriched format
  • Source
  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: Significant renal artery stenosis (RAS) may lead to left ventricle (LV) hypertrophy and diastolic function (DF) impairment through complex mechanisms: activation of cytokines and/or systolic and diastolic blood pressure (SBP, DBP) increase. To assess interrelations between LV mass (LVM), DF and cytokines in patients undergoing renal artery stenting (PTA, percutaneous angioplasty of renal artery). The study group comprised 72 subjects (44.4% men), 64.1 ± 9.9 years with RAS referred to PTA. SBP, DBP, transforming growth factor beta1 (TGF-β1), aldosterone, B-type natriuretic peptide (BNP) levels and change in LVM and LVM index (LVMI) and DF (Evel, e'vel, E/A ratio, E/e' ratio, Artime-Atime) on echocardiography were assessed preprocedurally, and three and 12 months postprocedurally. TGF-β1 level decreased from 13.3 ± 14.9 to 8.6 ± 8.0 ng/mL (p = 0.027), while BNP increased from 89.1 ± 86.3 to 131 ± 105 pmol/mL (p < 0.001). A significant reduction in LVMI in women (79.4 ± 16.9 vs. 95.7 ± 18.5 g/m², p < 0.001) and men (77.2 ± 16.8 vs. 100.1 ± 19.7 g/m², p < 0.001) was found at 12 months vs. baseline. Degree of LVM reduction correlated with baseline LVM (p < 0.001; r = -0.612) and e'vel (p = 0.05; r = 0.230), but not with BP values. Among DF parameters, only e'vel increased significantly at 12 months (5.54 ± 1.57 vs. 5.92 ± 1.65 cm/s; p = 0.039), while A/E and E/e' ratio, Artime-Atime remained similar (p = 0.457, p = 0.283 and p = 0.258). Factors associated with e'vel increase ≥ 0.3 cm/s at 12 months were baseline LVM < 165 g (p = 0.043, RR = 1.39, CI 1.01-1.46), Evel (p = 0.015, RR = 1.26, CI 1.15-1.52), e'vel (p < 0.001, RR = 1.42, CI 1.18-1.7), DBP decrease > 10 mm Hg (p = 0.055, RR = 1.2, CI 1.0-1.44) and TGF-β1 > 8 ng/mL (p = 0.024, RR = 1.24, CI 1.03-1.49) at 12 months. Significant LVMI reduction was observed after PTA of RAS, but it was independent of BP reduction. e'vel increase was independently associated with baseline LVM, Evel, e'vel, and 12 month decrease in DBP > 10 mm Hg.
    Kardiologia polska 01/2013; 71(2):121-8. DOI:10.5603/KP.2013.0003 · 0.52 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: Microparticles (MPs) are small vesicles between 100 and 500 nm, released from different cells including blood, endothelium, smooth muscle, and retina cells. MPs are produced during shedding process in response to some stressing and stimulating factors, as well as during apoptosis. The cellular machinery leading to MP shedding involves the loss of the plasma membrane asymmetry and phosphatidylserine externalization with an increase in cytosolic calcium concentrations. MPs not only transfer membrane proteins from the cells of their origin but also convey phospholipids and microRNA to the distant cells. Some of these macromolecules have neoangiogenetic properties (factor XII, tissue factor or mitogen-activated protein kinases) or participate in modulation of vascular senescence or remodeling (miRNAs). AREAS COVERED: The authors summarise recent knowledge about MP biology and pathophysiology. The mechanisms involved in MP release are discussed, and special emphasis is placed on clinical studies, which document their proangiogenic role in diabetic retinopathy and vascular aging. EXPERT OPINION: The pharmacological control of phospholipid moieties in the plasma membrane and the regulation of the MP shedding remains a challenge in the early stage of diabetic retinopathy and vascular aging.
    Expert Opinion on Therapeutic Targets 05/2012; 16(7):677-88. DOI:10.1517/14728222.2012.691471 · 4.90 Impact Factor
  • Source
    International journal of cardiology 04/2012; 157(3):411-3. DOI:10.1016/j.ijcard.2012.03.140 · 6.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Incidence of patent foramen ovale (PFO) has been estimated at 25% in the general population and 6% for larger defects. Data on the relationship between PFO morphology and the risk of stroke are limited. PFO closure has become a common practice in many centres, although recent guidelines limit indications for such treatment to patients with cryptogenic (recurrent) stroke. Aim: To investigate whether PFO morphology assessed by transoesophageal echocardiography (TOE) differed between patients with symptoms and those who had an asymptomatic PFO. Methods: We analysed 88 consecutive patients (48 female, 40 male; mean age 36.1 ± 16.2 [range 18-59] years) who underwent TOE before transcatheter PFO closure due to a cryptogenic cerebrovascular event (Group I) and compared them to 88 consecutive patients (49 female, 39 male; mean age 35.7 ± 14.2 [range 18-57] years) with an asymptomatic PFO found incidentally on TOE (Group II). The diagnosis of stroke was based on the occurrence of a new acute focal neurological deficit, with neurological signs and symptoms persisting for 〉 24 h, subsequently confirmed by computed tomography and/or magnetic resonance imaging. Multiplane TOE was conducted as per guidelines using commercially available instruments. The interatrial septum was viewed in the transverse midoesophageal 4-chamber view and the longitudinal biatrial-bicaval view. PFO was diagnosed with intravenous injections of agitated saline while the patient was at rest and during the Valsalva manoeuvre. We analysed PFO size (resting and maximal separation of the septum primum and secundum during the Valsalva manoeuvre), tunnel length (maximal overlap of the septum primum and secundum), presence of an atrial septal aneurysm (excursion 〉 15 mm), shunt severity (mild: 3-5, moderate: 6-25, severe 〉 25 microbubbles) and prominence of the Eustachian valve. Results: The two groups did not differ with respect to age and sex distribution. Group I showed larger PFO size (maximal separation 3.9 ± 1.4 vs. 1.3 ± 1.3 mm, p 〈 0.0001), longer tunnel length (14 ± 6 vs. 12 ± 5.5 mm, p 〈 0.05) and a greater frequency of atrial septal aneurysm (55% vs. 15%, p 〈 0.0001) compared to Group II (controls). Group I was also characterised by a higher proportion of large PFOs (≤ 4 mm; 50% vs. 18%, p 〈 0.001) and severe shunt (40% vs. 2%, p 〈 0.0001). Conclusions: PFO in symptomatic patients is larger in size, has a longer tunnel and is more frequently associated with atrial septal aneurysm. Asymptomatic patients with PFO characteristics similar to that seen in stroke patients require more careful clinical evaluation. It may be debated whether such patients should be recruited to prospective trials to evaluate indications for PFO closure in stroke prevention.
    Kardiologia polska 01/2012; 70(12):1258-1263. · 0.52 Impact Factor
  • Postepy w Kardiologii Interwencyjnej / Advances in Interventional Cardiology 01/2012; 1:66-69. DOI:10.5114/pwki.2012.28072 · 0.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The rate of early complications of carotid artery stenting (CAS) should not exceed 3% in asymptomatic and 6% in symptomatic patients. However, some recent studies/registries failed to reach this threshold, fueling a debate on the role of CAS in the treatment of patients with carotid artery stenosis. To evaluate 30-day safety of CAS using different embolic protection devices and different stent types according to the tailored-CAS algorithm and to identify risk factors for complications. Between 2002 and 2010, we performed 1176 CAS procedures in 1081 patients (age 38-86 years, mean 66.3 ± 8.4 years, 51.5% symptomatic) according to the tailored-CAS algorithm that included extracranial ultrasound and computed tomography angiography to select the most appropriate embolic protection device (EPD) and stent type. Proximal EPD and closed-cell (CC) stents were preferentially used for high-risk lesions (HR - soft/thrombus-containing/tight/ulcerated, 36.14% of all lesions) and in symptomatic patients. Procedural success rate was 99.8%. In symptomatic patients, proportion of HR lesions was higher (41.1%) than in the asymptomatic group (30.8%, p = 0.001) and the usage of CC stents (76.2% vs 71.7%, p = 0.103) and proximal EPD (P-EPD, 34.8% vs 27.7% among asymptomatic patients, p = 0.010) was more frequent. CC stents were used in 82.4% of CAS procedures involving HR lesions (vs 69.1% for non-HR lesions, p < 0.01), and P-EPD were used in 83.1% of procedures involving HR lesions (vs 2.5% for non-HR lesions, p < 0.001). In-hospital complications included 6 (0.55%) deaths, 1 (0.08%) major stroke and 19 (1.61%) minor strokes. No myocardial infarctions (MI) were noted. Among 7 (0.59%) cases of hyperperfusion syndrome, 2 were fatal. Thirty-day complication rate (death/any stroke/MI) was 2.38%. Age > 75 years was a predictor of death (p = 0.015), and prior neurological symptoms were a predictor of death/stroke (p = 0.030). There were 4 cases of periprocedural embolic cerebral artery occlusion, all treated with combined intracranial mechanical and local thrombolytic therapy. CAS with EPD and stent type selection on the basis of thorough non-invasive diagnostic work-up (tailored- -CAS) is safe. Advanced age was associated with an increased risk of death and the presence of prior neurological symptoms was a predictor of death/stroke at 30 days. With the tailored-CAS approach, high-risk lesion features (soft/thrombus- -containing/tight/ulcerated) are eliminated as a risk factor. Hyperperfusion syndrome is a severe CAS complication which may lead to intracranial bleeding and death. Acute, iatrogenic embolic cerebral artery occlusion is rare and may be managed by combined intracranial mechanical and local thrombolytic therapy.
    Kardiologia polska 01/2012; 70(4):378-86. · 0.52 Impact Factor
  • Anna Kablak-Ziembicka, Tadeusz Przewłocki
    Journal of Endovascular Therapy 08/2011; 18(4):527-30. DOI:10.1583/11-3400C.1 · 3.59 Impact Factor
  • Tadeusz Przewłocki
    Kardiologia polska 01/2011; 69(8):772-3. · 0.52 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the relationship between carotid intima-media thickness (CIMT), biomarkers, atherosclerosis extent and a two-year cardiovascular (CV) event risk in patients with arteriosclerosis. The CIMT, levels of high-sensitivity C-reactive protein (hs-CRP), tumour necrosis factor alpha (TNF-α), transforming growth factor beta (TGF-β), interleukin-6 (IL-6), interleukin-10 (IL-10), and NT-proBNP were measured in 279 subjects with atherosclerotic disease, mean age 64.1 ± 9.6 years. The patients were included when they had artery stenosis ≥ 50% in one, two, three or four arterial territories (coronary, supra-aortic, renal and/or lower limb arteries), and this was found in 97, 80, 69 and 33 patients, respectively. During a two-year follow-up, the incidences of CV death, myocardial infarction, ischaemic stroke and lesion progression were recorded. The identified independent predictors of ≥ 3-territorial stenoses ≥ 50% were CIMT > 1.3 mm (RR 1.72; p < 0.001), hs-CRP > 5 mg/dL (RR 1.28; p = 0.005), IL-6 > 6.5 pg/mL (RR 1.08; p = 0.089), IL-10 (RR 0.86; p = 0.002), diabetes (RR 1.11; p = 0.027), total-cholesterol (RR 1.21; p < 0.001), creatinine (RR 1.15; p = 0.004) and body mass index (RR 0.85; p = 0.001). During a two-year follow-up, CV events occurred in 52 (18.6%) patients. The CIMT > 1.3 mm (p < 0.001), diabetes (p = 0.018), TNF-α > 6 pg/mL (p = 0.018), LDL-cholesterol > 3.35 mmol/L (p = 0.012) and NT-proBNP (p = 0.074) were independent CV event risk factors associated with a 27%, 14%, 15%, 15% and 11% higher CV risk, respectively. However, after adjustment for a baseline location of artery stenosis ≥ 50%, CIMT became a non-significant predictor (p = 0.245). Levels of hs-CRP, IL-6, IL-10 are independently associated with atherosclerosis extent, while TNF-α and NT- -proBNP are mostly related to a two-year CV event risk. The CIMT > 1.3 mm seems to be a clinically relevant marker associated with atherosclerosis extent and CV risk, although CV event risk is primarily related to the baseline stenosis location.
    Kardiologia polska 01/2011; 69(10):1024-31. · 0.52 Impact Factor
  • Tadeusz Przewłocki
    Kardiologia polska 09/2010; 68(9):994-5. · 0.52 Impact Factor
  • Tadeusz Przewłocki, Andrzej Gackowski
    Kardiologia polska 11/2009; 67(11):1207-9. · 0.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular diseases are the number one killer in the developed countries, accounting for approximately half of all deaths, with the leading causes being myocardial infarction and ischaemic stroke. In line with the ageing population, the prevalence of coronary artery disease (CAD), lower extremity peripheral arterial disease (PAD), supra-aortic arterial disease (SAD) and renal stenosis (RAS) is increasing. Polyvascular atherosclerosis (PVA) coexisting in several territories has an adverse effect on cardiovascular morbidity and mortality. To determine prevalence, coexistence and predictors of significant PAD, SAD and RAS in patients with suspected CAD. Based on angiography, the frequency of coexisting CAD, SAD, PAD and RAS (stenosis > or =50%) was determined in 687 (487 male) consecutive patients, aged 63.5 +/- 9.1 years, referred for coronary angiography. Significant CAD was found in 545 (79.3%) patients (1-vessel in 164; 2-vessel in 157; 3-vessel in 224). SAD, RAS and PAD were found in 136 (19.8%), 55 (8%), and 103 (15%) patients, respectively. Of the 545 patients with confirmed CAD, 346 (63.5%) had stenoses limited to coronary arteries. 2-, 3- and 4-level PVA was found in 130 (23.8%), 61 (11.2%) and 8 (1.5%) patients, respectively. Of the 142 patients without CAD, 127 (89.4%) had no significant stenoses elsewhere, 12 (8.5%) had 1 extracoronary territory and 3 (2.1%) had 2-territory involvement. Backward stepwise binary logistic regression analysis showed the following independent predictors of at least 2-level PVA: 2- and 3-vessel CAD (p < 0.001), hyperlipidaemia (p = 0.067), smoking (p < 0.001), creatinine level > or = 1.3 ml/dl (p < 0.001), lower extremities claudication (p < 0.001) and female gender (p = 0.003). The relative risk of having at least 2-territory PVA was 15.7-fold higher in patients with claudication, 2.1-fold in patients with multivessel CAD, 2.8-fold for serum creatinine level > 1.3 mg/dl; and 1.9-fold, 2.4-fold and 2-fold in patients with hyperlipidaemia, smokers and women, respectively. Conclusions: Significant atherosclerosis in extracoronary arterial territories is present in 36% of patients with documented CAD. With advancing PVA, accumulation of atherosclerosis risk factors, previous atherothrombotic events and more severe CAD is observed.
    Kardiologia polska 08/2009; 67(8A):978-84. · 0.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In patients with coronary artery disease (CAD), the presence of atherosclerotic lesions in other vascular beds is associated with a markedly worse prognosis. To determine the prevalence and predictors of extracranial supra-aortic artery atherosclerotic disease (SAD) in patients with suspected CAD. Supra-aortic artery angiography was performed in 379 consecutive patients aged 64.2 +/- 8.8 years (231 male) referred for coronary angiography. Clinical and laboratory data (total cholesterol, LDL, HDL cholesterol, hs-CRP, creatinine level) and left ventricular ejection fraction were analysed. Significant stenosis (> or =50% by quantitative angiography) within at least one main branch of the coronary arteries was found in 314 (82.8%) patients, including 87 (27.7%), 96 (30.6%) and 131 (41.7%) with 1-vessel, 2-vessel, and 3-vessel CAD, respectively. Among all 379 patients, stenosis > or =50% of the carotid artery was documented in 9.5%, vertebral in 13.7%, and subclavian in 7.4% of patients. We found 130 stenoses > or =50% within the supra-aortic arteries in 90 patients (23.7% of the whole study group, and 28.7% of CAD patients), including 42 internal carotid artery stenoses in 36 patients, 58 vertebral artery stenoses in 52, and 30 subclavian stenoses in 28 patients. In 24 (6.3%) patients more than one SAD was present. The SAD > or =50% was found in 8 (12.3%) patients without significant CAD, in 22 (25.3%), 17 (17.7%) and 43 (32.8%) with 1-, 2- and 3-vessel CAD, respectively (p = 0.001). Independent predictors of SAD > or =50% identified by multivariate analysis were: previous neurological ischaemic event (p = 0.001), CAD (p = 0.015), creatinine level (p = 0.031), male gender (p = 0.001), claudication (p < 0.001) and low HDL cholesterol (p = 0.033). The following independent predictors of vertebral and/or subclavian artery stenosis > 50% were identified: CAD severity (p = 0.002), creatinine level (p = 0.024), male gender (p = 0.013), claudication (p < 0.001) and low HDL cholesterol level (p = 0.059). In a large patient sample, we have found that significant supra-aortic atherosclerosis is present in a quater of patients with suspected CAD. Importantly, SAD prevalence increases with CAD severity. Previous neurological ischaemic event, CAD, creatinine level, male gender, claudication and hyperlipidaemia were identified as independent predictors of SAD > or =50%.
    Kardiologia polska 08/2009; 67(8A):985-91. · 0.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In patients with severe degenerative aortic stenosis (DAS) the operative mortality risk is 3% for isolated aortic valve replacement (AVR), but it significantly increases in patients with concomitant coronary artery disease (CAD) and internal carotid artery stenosis (ICAS). To assess the frequency of ICAS > or = 50% and factors determining its occurrence in patients with severe calcified DAS referred for AVR. The study included 104 patients (67 men), aged 63.4+/-8.4 years, with symptomatic moderate-to-severe DAS (aortic valve area <1.5 cm2) undergoing coronary angiography prior to valve surgery. In all patients Doppler ultrasound of carotid arteries was performed with the assessment of lumen stenosis. Significant CAD, defined as at least one lumen reduction > or = 50% in a main coronary artery, was found in 44 (42.3%) patients and ICAS > or = 50% in 13 (12.5%) patients. Among patients with DAS, 12 (27.3%) out of 44 patients with significant CAD and 1 (1.7%) out of 60 patients without CAD had ICAS > or = 50% (p <0.001). The frequency of ICAS > or = 50% increased with advancing CAD, occurring in 4 (25%) out of 16 patients with 1-vessel CAD, 3 (25%) out of 12 with 2-vessel CAD and (31.3%) out of 16 patients with 3-vessel CAD (p <0.001). The independent ICAS predictors by multivariate regression analysis were identified as: concomitant CAD (p <0.001), diabetes (p=0.054), cigarette smoking (p=0.08) and decreased left ventricular ejection fraction (p=0.039). ICAS > or = 50% was found to be an independent predictor of CAD (p=0.002). ICAS > or = 50% occurs in 13% of patients with isolated DAS and in 27% of those with DAS and CAD. Independent ICAS risk factors were identified as CAD, diabetes and cigarette smoking. Duplex ultrasound of carotid arteries should be considered in patients with DAS and concomitant CAD prior to AVR.
    Kardiologia polska 09/2008; 66(8):837-42; discussion 843-4. · 0.52 Impact Factor

Publication Stats

104 Citations
77.05 Total Impact Points

Institutions

  • 2000–2014
    • Jagiellonian University
      • • Institute of Cardiology
      • • Department of Clinical Biochemistry
      Cracovia, Lesser Poland Voivodeship, Poland
  • 2000–2012
    • Krakowski Szpital Specjalistyczny im. Jana Pawła II
      Cracovia, Lesser Poland Voivodeship, Poland
  • 2005–2010
    • Collegium Medicum of the Jagiellonian University
      • Institute of Cardiology
      Cracovia, Lesser Poland Voivodeship, Poland
  • 2004–2006
    • Uniwersytet Papieski Jana Pawła II w Krakowie
      Cracovia, Lesser Poland Voivodeship, Poland